Clinical aspects of imatinib therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Imatinib is an inhibitor of the ABL, platelet-derived growth factor receptors, and KIT tyrosine kinases. Given the pathogenetic role of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, this was the first disease selected for clinical trials with imatinib. In the clinical trials, patients in all phases of the disease responded to imatinib and experienced minimal toxicity. Responses in patients with chronic phase disease have been durable, thus far. Clinical trials with imatinib were expanded and there are now examples of malignancies driven by each of the targets of imatinib where remarkable results have been seen. The rationale for the use of imatinib in these various diseases and the clinical trial results will be reviewed.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages391-410
Number of pages20
Volume167
DOIs
StatePublished - 2005

Publication series

NameHandbook of Experimental Pharmacology
Volume167
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Clinical Trials
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Toxicity
Imatinib Mesylate
Chronic Disease
Neoplasms
PDGF receptor tyrosine kinase

Keywords

  • BCR-ABL
  • CML
  • Imatinib

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Druker, B. (2005). Clinical aspects of imatinib therapy. In Handbook of Experimental Pharmacology (Vol. 167, pp. 391-410). (Handbook of Experimental Pharmacology; Vol. 167). https://doi.org/10.1007/3-540-26670-4-14

Clinical aspects of imatinib therapy. / Druker, Brian.

Handbook of Experimental Pharmacology. Vol. 167 2005. p. 391-410 (Handbook of Experimental Pharmacology; Vol. 167).

Research output: Chapter in Book/Report/Conference proceedingChapter

Druker, B 2005, Clinical aspects of imatinib therapy. in Handbook of Experimental Pharmacology. vol. 167, Handbook of Experimental Pharmacology, vol. 167, pp. 391-410. https://doi.org/10.1007/3-540-26670-4-14
Druker B. Clinical aspects of imatinib therapy. In Handbook of Experimental Pharmacology. Vol. 167. 2005. p. 391-410. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/3-540-26670-4-14
Druker, Brian. / Clinical aspects of imatinib therapy. Handbook of Experimental Pharmacology. Vol. 167 2005. pp. 391-410 (Handbook of Experimental Pharmacology).
@inbook{f252d66222804f2bbf6eb16a032db6ec,
title = "Clinical aspects of imatinib therapy",
abstract = "Imatinib is an inhibitor of the ABL, platelet-derived growth factor receptors, and KIT tyrosine kinases. Given the pathogenetic role of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, this was the first disease selected for clinical trials with imatinib. In the clinical trials, patients in all phases of the disease responded to imatinib and experienced minimal toxicity. Responses in patients with chronic phase disease have been durable, thus far. Clinical trials with imatinib were expanded and there are now examples of malignancies driven by each of the targets of imatinib where remarkable results have been seen. The rationale for the use of imatinib in these various diseases and the clinical trial results will be reviewed.",
keywords = "BCR-ABL, CML, Imatinib",
author = "Brian Druker",
year = "2005",
doi = "10.1007/3-540-26670-4-14",
language = "English (US)",
isbn = "9783540212423",
volume = "167",
series = "Handbook of Experimental Pharmacology",
pages = "391--410",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Clinical aspects of imatinib therapy

AU - Druker, Brian

PY - 2005

Y1 - 2005

N2 - Imatinib is an inhibitor of the ABL, platelet-derived growth factor receptors, and KIT tyrosine kinases. Given the pathogenetic role of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, this was the first disease selected for clinical trials with imatinib. In the clinical trials, patients in all phases of the disease responded to imatinib and experienced minimal toxicity. Responses in patients with chronic phase disease have been durable, thus far. Clinical trials with imatinib were expanded and there are now examples of malignancies driven by each of the targets of imatinib where remarkable results have been seen. The rationale for the use of imatinib in these various diseases and the clinical trial results will be reviewed.

AB - Imatinib is an inhibitor of the ABL, platelet-derived growth factor receptors, and KIT tyrosine kinases. Given the pathogenetic role of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, this was the first disease selected for clinical trials with imatinib. In the clinical trials, patients in all phases of the disease responded to imatinib and experienced minimal toxicity. Responses in patients with chronic phase disease have been durable, thus far. Clinical trials with imatinib were expanded and there are now examples of malignancies driven by each of the targets of imatinib where remarkable results have been seen. The rationale for the use of imatinib in these various diseases and the clinical trial results will be reviewed.

KW - BCR-ABL

KW - CML

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=84884483083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884483083&partnerID=8YFLogxK

U2 - 10.1007/3-540-26670-4-14

DO - 10.1007/3-540-26670-4-14

M3 - Chapter

AN - SCOPUS:84884483083

SN - 9783540212423

VL - 167

T3 - Handbook of Experimental Pharmacology

SP - 391

EP - 410

BT - Handbook of Experimental Pharmacology

ER -